U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07158918) titled 'ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors' on Aug. 08.
Brief Summary: This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.
Study Start Date: Aug. 06
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Intervention:
DRUG: ABL103
IV infusion
DRUG: KEYTRUDA(R) (pembrolizumab)
IV infusion
DRUG: Taxane
IV infusion
Recruitment Status: RECRUITING
Sponsor: ABL Bio, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....